Antitumor response and immunomodulatory effects of sub-microsecond irreversible electroporation and its combination with calcium electroporation
![Thumbnail](/bitstream/handle/123456789/148196/cancers-11-01763.pdf.jpg?sequence=3&isAllowed=y)
Peržiūrėti/ Atidaryti
Data
2019Autorius
Novickij, Vitalij
Čėsna, Robertas
Perminaitė, Emilija
Zinkevičienė, Auksė
Characiejus, Dainius
Novickij, Jurij
Šatkauskas, Saulius
Ruzgys, Paulius
Girkontaitė, Irutė
Metaduomenys
Rodyti detalų aprašąSantrauka
In this work, we have investigated the feasibility of sub-microsecond range irreversible electroporation (IRE) with and without calcium electroporation in vivo. As a model, BALB/C mice were used and bioluminescent SP2/0 myeloma tumor models were developed. Tumors were treated with two separate pulsed electric field (PEF) pulsing protocols PEF1: 12 kV/cm × 200 ns × 500 (0.006 J/pulse) and PEF2: 12 kV/cm × 500 ns × 500 (0.015 J/pulse), which were delivered with and without Ca2+ (168 mM) using parallel plate electrodes at a repetition frequency of 100 Hz. Both PEF1 and PEF2 treatments reduced tumor growth and prolonged the life span of the mice, however, the PEF2 protocol was more efficient. The delay in tumor renewal was the biggest when a combination of IRE with calcium electroporation was used, however, we did not obtain significant differences in the final mouse survival compared to PEF2 alone. Anti-tumor immune responses were also investigated after treatment with PEF2 and PEF2+Ca. In both cases the treated mice had enlarged spleens and increased spleen T cell numbers, lower percentages of suppressor cell subsets (conventional CD4+CD25+ Treg, CD4+CD25−DX5+ Tr1, CD8+DX5+, CD4+CD28−, CD8+CD28−), changed proportions of Tcm and Tef/Tem T cells in the spleen and increased amount of tumor cell specific antibodies in the sera. The treatment based on IRE was effective against primary tumors, destroyed the tumor microenvironment and induced an anti-tumor immune response, however, it was not sufficient for complete control of tumor metastasis.